Mettl3-Mediated m6A修改为FSGS提供了一个新的治疗目标
Fubin Zhu1, Hongzhi Li1, Xiang Li1
1Nephrosis Precision Medicine Innovation Center, School of Basic Medicine, Beihua University, Jilin, 132011, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 19, 2025
概括
类似于N6-adenosine-methyltransferase的3 (Mettl3) 调节了N6-methyladenosine (m6A) RNA甲基化在细胞中的作用. 失去Mettl3会导致焦点细分质硬化 (FSGS),这表明m6A修饰是FSGS的潜在治疗标.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 焦点细分质硬化 (FSGS) 是导致病的主要原因,通常与细胞损伤有关.
- 虽然已知遗传因素,但像FSGS中的N6-甲基氨酸 (m6A) 等表观遗传修饰的作用在很大程度上仍未被探索.
研究的目的:
- 调查N6-adenosine-methyltransferase-like 3 (Mettl3) 介导的m6ARNA修饰在FSGS病变发生中的作用.
- 探索Mettl3作为FSGS的潜在治疗点.
主要方法:
- 产生了 podocyte 特定的 Mettl3 淘汰赛小鼠 (Mettl3podko) 来研究 FSGS 的发展.
- 利用RNA测序 (RNA-seq) 和m6A免疫沉积RNA测序来分析基因表达变化.
- 采用RNA免疫沉试验和杂交连锁反应 (HCR) 分析来识别Mettl3标.
- 进行了功能损失和功能增益研究,并用m6A模拟化合物治疗FSGS小鼠模型.
主要成果:
- 在FSGS动物模型和患者的球体中观察到降低的m6ARNA水平.
- 梅特尔波德科小鼠表现出降低的波多细胞m6A水平,并发展出FSGS.
- 梅特尔3缺乏导致与裂口隔膜功能障碍相关的基因表达特征,将TJP1确定为梅特尔3标.
- 可能通过TJP1-CDC42通路进行的Mettl3-介导的m6A修饰对于 podocyte 功能至关重要.
- 在小鼠模型中,使用m6A模仿化合物的治疗改善了FSGS进展.
结论:
- 甲基3介导的m6ARNA修饰对于维持细胞结构和功能至关重要.
- 在防止FSGS发展方面,Mettl3起着至关重要的作用.
- 针对Mettl3-介导的m6A修饰为FSGS提供了一个有前途的治疗策略.
相关概念视频
01:26Protein Modifications in the RER
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...